After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst